BioSpace News Archive

TherapeuticsMD, Inc. announced that it has entered into an exclusive license and supply agreement with Theramex, a leading, global specialty pharmaceutical company dedicated to women’s health, to commercialize BIJUVA and IMVEXXY outside of the United States.

Companion Medical, Inc. today announced the addition of new features to the InPen system further increasing its utility for InPen users and their healthcare providers.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019. Michael Severino, vice chairman and president, will present at 10:00 a.m. Central time.

Health Catalyst®, Inc., a leading provider of data and analytics technology and services to health care organizations, announced today that INTEGRIS Health, Oklahoma’s largest not-for-profit health system, will use the Health Catalyst Data Operating System (DOS™) across its network to drive data-informed clinical, operational, and financial performance improvements.

Monarch Medical Technologies, the leader in precision insulin dosing for optimized inpatient glucose management, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of an additional feature of Monarch EndoTool SubQ, an insulin-on-board (IOB) algorithm.

Laxogenin 100™ body building supplement is the product every athlete or health conscious person has been waiting for!

Varian (NYSE: VAR) today announced it will be hosting its second FlashForward™ Consortium meeting at 12:00pm Tuesday, June 11th at the 58th annual Particle Therapy Co-Operative Group meeting (PTCOG) in Manchester, United Kingdom

Vyaire Medical, a leader in global respiratory care, announces the appointment of Lisa Rose, Chief Marketing and Innovation Officer, and Debra Goetz, Chief Brand and Digital Officer to the Vyaire Executive Leadership team.

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, is sending a new mailing to shareholders highlighting the experience of its three new highly qualified nominees standing for election to the Board of Directors

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, today reported that the previously announced business combination with Stellar Biotechnologies, Inc. (Nasdaq: SBOT) (“Stellar”), which was completed pursuant to a share exchange agreement, has closed.